Early antiretroviral therapy initiation in west Africa has no adverse social consequences: a 24-month prospective study
A retrospective cohort analysis comparing the efficacy of boosted protease inhibitor-based and efavirenz-based combination antiretroviral therapy in treatment-naïve people living with HIV with baseline resistance found that efavirenz-based treatment led to a shorter mean time to
undetectable viral load. A higher proportion of patients with nonnucleoside reverse transcriptase inhibitor related baseline resistance mutations in the efavirenz-treatment group achieved an undetectable viral load at both 6 and 12 months post-treatment initiation, compared with the boosted
protease-inhibitor-treatment group.
Supplementary content:http://links.lww.com/QAD/A930 .
Supplementary content:
Document Type: Research Article
Affiliations: 1: Imperial College London, South Kensington Campus 2: Chelsea and Westminster Hospital NHS Foundation Trust 3: Barts Healthcare NHS Trust, London, UK. 4: Imperial College London, South Kensington Campus, Chelsea and Westminster Hospital NHS Foundation Trust
Publication date: 17 July 2016
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content